CAR T-Cell Therapy Shows Mixed but Promising Results Against Lupus Kidney Disease

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease driven largely by autoreactive B cells. For patients who fail standard immunosuppressive treatments, particularly those with lupus nephritis (LN), therapeutic options are limited and prognosis can be poor. CAR T-cell therapy targeting CD19 has emerged as a compelling strategy to achieve deep B-cell depletion and potentially reset the immune system.

This open-label, single-arm pilot trial evaluated IM19, an autologous anti-CD19 CAR T-cell product, in six patients with refractory SLE and active renal disease. Following lymphodepletion conditioning, patients received IM19 infusions and were monitored through day 180. Repeat renal biopsies and single-cell RNA sequencing of peripheral blood mononuclear cells were performed to assess both histological and immunological changes.

Systemic disease activity improved meaningfully across the cohort, with median SLEDAI-2000 scores falling from 12 to 4 by day 90 and holding at 5 by day 180. The safety profile was favorable, with cytokine release syndrome being mild and manageable. However, kidney responses were notably heterogeneous: two complete responders, two partial responders, and two nonresponders. Biopsy findings post-treatment showed absence of B-cell infiltration but revealed dominant chronic fibrotic changes and podocytopathies, suggesting that non-immunological mechanisms may drive treatment-resistant nephritis in some patients.

A mini-review of CAR T-cell therapy studies in LN found a pooled complete renal response rate of 72.4%, with advanced age identified as a predictor of suboptimal response. Single-cell analysis confirmed B-cell reconstitution in three of six patients by day 180, highlighting variability in immune reset durability.

These findings suggest that while CAR T-cell therapy offers a promising systemic immunological reset in refractory SLE, renal outcomes depend heavily on pre-existing structural kidney damage, podocyte pathology, and patient age. Larger trials with careful patient selection will be essential to optimize this approach.